The current study aimed at investigating the role of oxidative stress, liver enzymatic activity, and serum chemical parameters to assess hepatotoxicity. Several thousands of chemicals are ingested as food additives. The liver is the first filter of portal blood draining of the alimentary tract. The hepatic enzymes metabolize these components. There are 2 distinct phases of metabolism. In phase 1, the compounds undergo enzymatic oxidation, reduction, or hydrolysis. During these processes some metabolic intermediates are produced. These toxic intermediates such as reactive oxygen species (ROS) are highly reactive and damage macromolecules such as DNA, lipids, proteins, and carbohydrates. In phase 2, these toxic intermediates are conjugated with some compounds such as GSH and amino acids to form water soluble metabolites that are less toxic and more amenable to renal excretion (
7). Oxidative stress results from excessive levels of ROS. ROS attacks are responsible for cell damage and the targeted cells are presented by the cell membranes rich in unsaturated fatty acids and sensitive to oxidation reactions (
8). MDA is a product of lipid peroxidation used as an indicator in oxidative damages. The level of MDA was a little different between the control and 1000 ppm groups. Furthermore, FRAP level altered between the groups. A significant decrease was observed in the FRAP levels. FRAP is a measure of the antioxidant power, based on the reduction of ferrous ions by the effect of the reducing power of samples, and contributed by low molecular weight antioxidants such as vitamins C and E, bilirubin, and uric acid (
9). The reduction in the total GSH content of the liver tissue was observed at 100 ppm. But, this reduction increased at 1000 ppm. It increased in dose of 1000 ppm because of its reproduction.
Oxidative stress results from excessive levels of ROS. Presence of antioxidants has an important role on the prevention of oxidative changes. It requires a considerable degree of antioxidant against peroxidation (
10). Therefore, antioxidants can lower the occurrence of oxidative stress. Hepatic antioxidant capacity and GSH level decreased significantly in intermediate dose (100 ppm), while these levels increased in the high dose. It is of interest to note that it was probably associated with the synthesis of GSH and other antioxidant agents. GSH is mostly involved in the oxidative defence.
Enzymes such as SGPT and SGOT were also measured to assess liver toxicity. The levels of enzymes are the main indices of liver injury. SGPT activity is the most frequently relied biomarker of hepatotoxicity. To the authors’ best knowledge, liver enzyme plays an important role in amino acid metabolism and gluconeogenesis. The estimation of this enzyme is a more specific test to detect liver abnormalities. This enzyme detects hepatocellular necrosis. SGOT is another liver enzyme that aids in producing proteins. It also helps to detect hepatocellular necrosis (
11). The enzymatic activities did not significantly change in the intervention groups, compared with the control group. It is assumed that this product does not induce hepatotoxicity.
The liver is involved in the metabolism of fat and proteins. No significant difference was observed in biochemistry parameters except glucose in high dose (
Table 3). In addition, the obtained results were in accordance with those of the other studies that showed that oral stevioside was safe and supported the well-established tolerability during long-term uses as sweetener (
12). Furthermore, in a study, serum biochemical parameters including lipid and glucose showed no significant changes (
1). JECFA reviewed the safety of steviol glycosides in 2000, 2005, 2006, 2007, and 2009 and established an ADI for steviol glycosides (expressed as steviol equivalents) of 4 mg/kg/day.
In conclusion, the current study demonstrated that stevioside did not induce hepatotoxicity in the liver tissue by assessing the activities of SGOT, SGPT, and chemical parameters, as reported in previous studies. The data of the current study recommended no acute liver injury to stevioside. However, further studies are needed to apply in vivo mammalian toxicity test to predict liver toxicity in humans.